Khoso Baluch - 24 Jul 2025 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role: Director
Signature: /s/ Khoso Baluch by Neda Sharifi, as Attorney-in-Fact
Issuer symbol: PCSA
Transactions as of: 24 Jul 2025
Net transactions value: $0
Form type: 4
Filing time: 28 Jul 2025, 16:19:40 UTC
Previous filing: 17 Jul 2025
Next filing: 13 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Baluch Khoso	Director	C/O PROCESSA PHARMACEUTICALS, INC., 601 21ST STREET SUITE 300, VERO BEACH	/s/ Khoso Baluch by Neda Sharifi, as Attorney-in-Fact	28 Jul 2025	0001686223

This filing has been restated, see here for the amended filing

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PCSA	Restricted Stock	Award	$0	+175,299	+562%	$0.000000	206,505	24 Jul 2025	Common Stock	175,299	$0.000000	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan ("Omnibus Plan"), of which 125,999 shares are subject to stockholder approval of the revised Omnibus Plan.
F2	The restricted stock vest on the earlier of June 30, 2026 or the next annual meeting of stockholders, subject to certain distribution requirements.